# Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer

> **NCT00093548** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** alpha fetoprotein adenoviral vector vaccine
- **BIOLOGICAL:** alpha fetoprotein plasmid DNA vaccine
- **BIOLOGICAL:** sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant

## Key facts

- **NCT ID:** NCT00093548
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093548, "Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00093548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*